People In Business NYSE 4

USA

Cantel Medical vice chairman George L. Fotiades sells 17 October 2017

NEWS BITES - PEOPLE IN BUSINESS

Cantel Medical (NYSE:CMD) Vice Chairman George L. Fotiades sold 6,000 shares worth $US571,386 on October 13. The selling price was $US95.23.

HTTP link to original article

https://www.sec.gov/Archives/edgar/data/19446/000001944617000052/xslF345X03/edgar.xml

George L. Fotiades (Reported Selling; trailing 12 months)
MonthNo. of SharesPrice, USDValue, USD
October 17, 20176,00095.23571,386

Original news release

Source: SEC

SECTION 1 BIOGRAPHY GEORGE L. FOTIADES, VICE CHAIRMAN

Partner, Healthcare investments at Diamond Castle Holdings, LLC, a private equity firm, since April 2007. For more than five years prior thereto, Mr. Fotiades served as President and COO of Cardinal Health, Inc., a leading provider of healthcare products and services. Mr. Fotiades is also a director of Prologis, Inc. (NYSE), a leading owner, operator and developer of industrial real estate, and AptarGroup Inc. (NYSE), a leader in the global dispensing systems industry. He has served as Vice Chairman of the Board of Cantel and a non-executive member of the Office of the Chairman since April 2008. Mr. Fotiades' extensive experience in executive management of global operations, strategic planning, and sales and marketing, particularly in the healthcare industry, qualifies him to serve on the Board.

SECTION 2 CANTEL MEDICAL CORP. PRICE PERFORMANCE SCORECARD (NYSE:CMD):

+ Cantel Medical Corp. is placed 827/2,553 in the BSS News Bites ranking of price performance of NYSE stocks in the past year, a percentile ranking of 67.

2.1 MCap History:

In the past 5 years Market Capitalization has increased by $US3.5 billion from $US462.9 million to $US4 billion. Based on a dynamic start date of 5 years ago, there has been no decline in MCap over the last 5 years.

PriceMCap (US$ M)
Last$US95.693,991.6
1 Year ago$US75.423,137.7
2 Years ago$US54.662,278.1
3 Years ago$US38.681,596.2
4 Years ago$US31.781,314.8
5 Years ago$US17.0462.9

2.2 Moving Annual Return (Trailing 12 months):

Based on a dynamic start date of 5 years ago, the Moving Annual Return has consistently exceeded 10.0%.

CMDCloseDividendsCapital Gain %% YieldAnnual Return %
Last Traded Oct 17$US96.3414.0c27.20.227.3
1 Year ago$US75.7612.0c33.80.234
2 Years ago$US56.6310.0c52.60.352.9
3 Years ago$US37.119.0c100.310.3
4 Years ago$US33.737.37c100.10.4100.5

Close 5 years ago $US16.86.

2.3 Present Value of $US1000 invested in the past

The present value of $US1000 invested a year ago is $US1,271

PV$10001-week1-month1-year
CMD.NYSE9921,1411,271
S&P 500 Index1,0051,0241,199

SECTION 3 CANTEL MEDICAL CORP. FINANCIALS AND GROWTH PERFORMANCE SCORECARD (NYSE:CMD):

3.1 Key Financials (All figures percent)

EPS Growth has improved from 9.5% in 2014 to 18.8% in 2017, Return on Equity has improved from 11.8% in 2014 to 13.6% in 2017 and Revenue Growth has improved from 15.0% in 2014 to 15.9% in 2017.

CMDRevenue GrowthEPS GrowthOperating MarginROE
201715.918.814.413.6
201617.725.214.613.2
201515.610.613.911.8
2014159.514.511.8

3.2 Revenue and Net Profit

In the last 3 years Compound Annual Growth Rate (CAGR) averaged 16.4% for Total Revenue and 18.2% for Net Profit.

DescriptionAnnual ($US M)3-year Avg ($US M)3-year CAGR %
Total Revenue770.2666.616.4
EBITDA110.5103.57.1
Operating Profit110.595.515.9
Net Profit71.459.818.2

CAGR = Compound Annual Growth Rate

3.3 Performance (All figures in %)

Net Profit Margin 3-year average is 8.9% and Return on Equity 3-year average is 12.9%.

DescriptionAnnual3-year Avg
EBITDA Margin14.415.7
Operating Profit Margin14.414.3
Net Profit Margin9.38.9
Return on Equity13.612.9
Return on Assets9.18.6
Return on Capital Employed16.315.9

3.4 High Performance Indicators:

DescriptionValueRank In NYSE Market
3-mo Price Change %25.91In Top 6%
Price/MAP501.13In Top 6%
Price/MAP2001.21In Top Quartile
Interest Cover25.7In Top Quartile
Total Debt to Equity0.2In Top Quartile
Return on Assets [ROA] %9.1In Top Quartile
Price Change %0.5In Top Quartile
Return on Capital Employed [ROCE] %16.3In Top Quartile

SECTION 4 CANTEL MEDICAL CORP. MARKET POSITION AND GLOBAL RANK (NYSE:CMD):

4.1 Market Position

Cantel Medical Corp. (NYSE:CMD), NYSE's 13th largest Medical Equipment company by market cap, jumped $US17.08 (or 21.7%) year to date in 2017 to close at $US95.69. The stock has a 6-month USD relative strength of 88 which means in USD terms it is outperforming 88% of its 47,796 global peers. A price rise combined with a high relative strength is a bullish signal. Compared with the S&P 500 Index which has risen 14.2% YTD, this is a relative price increase of 7.5%. The average daily volume of 137,508 shares so far in 2017 was 0.8 times the average daily volume in 2016. In 2017 the market cap has jumped $US706.6 million.

4.2 Global Rank

Global Rank [out of 47,796 stocks]

DescriptionValueRankQuartile
MCap (US$)4B3,200Top
Total Assets (US$)786.4M10,982Top
Revenue (US$)770.2M7,595Top
Net Profit (US$)71.4M6,135Top
Return on Equity %13.68,595Top
Net Profit Margin %9.311,968Second
Price to Book45.132,735Third
Price Earnings55.618,481Second
Yield %0.120,790Second
PV$1000 (1Year) US$1,27114,352Second
US$ Change (1Year) %26.513,586Second
Rel Strength 6 Mo (US$)885,607Top

SECTION 5 OTHER DIRECTORS OF CANTEL MEDICAL CORP.

Jorgen B. Hansen, Chief Executive Officer & President & Chief Operating Officer

Charles M. Diker, Chairman

Peter G. Clifford, Chief Financial Officer & Executive Vice President

Ann E. Berman, Director

Joseph M. Cohen, Director

Bruce Slovin, Director

Laura Forese, Director

Mark N. Diker, Director

Alan R. Batkin, Director

Ronnie Myers, Director

George L. Fotiades, Vice Chairman

Craig A. Sheldon CPA, Senior Vice President

Eric W. Nodiff, Senior Vice President & Corporate Secretary

Dottie Donnelly Brienza, Senior Vice President

Steven C. Anaya, Vice President

SECTION 6 CANTEL MEDICAL CORP. ACTIVITIES

Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Its products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. It also provides technical maintenance for its products and offer compliance training services for the transport of infectious and biological specimens.

SECTION 7 RECENT NEWS ON DIRECTORS

7.1 REPORTED STOCK AWARDS

12 October 2017

Cantel Medical chairman Charles M. Diker awarded shares

Cantel Medical (NYSE:CMD) chairman Charles M. Diker, was awarded 1,300 shares worth $US123,461 on October 10.

12 October 2017

Cantel Medical vice chairman George L. Fotiades awarded shares

Cantel Medical (NYSE:CMD) vice chairman George L. Fotiades, was awarded 520 shares worth $US49,384 on October 10.

02 August 2017

Cantel Medical director Ronnie Myers awarded shares

Cantel Medical (NYSE:CMD) director Ronnie Myers, was awarded 875 shares worth $US64,925 on July 31.

01 August 2017

Cantel Medical vice chairman George L. Fotiades awarded shares

Cantel Medical (NYSE:CMD) vice chairman George L. Fotiades, was awarded 875 shares worth $US64,925 on July 31.

01 August 2017

Cantel Medical director Laura Forese awarded shares

Cantel Medical (NYSE:CMD) director Laura Forese, was awarded 875 shares worth $US64,925 on July 31.

01 August 2017

Cantel Medical director Alan R. Batkin awarded shares

Cantel Medical (NYSE:CMD) director Alan R. Batkin, was awarded 875 shares worth $US64,925 on July 31.

01 August 2017

Cantel Medical director Mark N. Diker awarded shares

Cantel Medical (NYSE:CMD) director Mark N. Diker, was awarded 875 shares worth $US64,925 on July 31.

7.2 SHAREHOLDER VALUE ADDED BY DIRECTORS

01 August 2017

Jorgen B. Hansen starts second year as Cantel Medical CEO

Jorgen B. Hansen was appointed CEO of Cantel Medical (NYSE:CMD) one year ago on August 01, 2016. The shares were up from $US68.2 to $US74.2 and the total annualized return to shareholders (TRS) since appointment is 9%. The present value of USD1,000 (PV1000) invested on the appointment date is now worth $US1,090, a gain of $US88 and dividend reinvested of $US2.

16 June 2017

Ronnie Myers starts second year as Cantel Medical Director

Ronnie Myers was appointed Director of Cantel Medical (NYSE:CMD) one year ago on June 16, 2016. The shares were up from $US72.2 to $US75.9 and the total annualized return to shareholders (TRS) since appointment is 5.4%. The present value of USD1,000 (PV1000) invested on the appointment date is now worth $US1,054, a gain of $US52 and dividend reinvested of $US2.

7.3 RECENT REPORTED SELLING

05 October 2017

Cantel Medical director Mark N. Diker sells

Cantel Medical (NYSE:CMD) Director Mark N. Diker sold 7,000 shares worth $US692,329 on October 03. The selling price was $US98.90.

04 October 2017

Cantel Medical chairman Charles M. Diker sells

Cantel Medical (NYSE:CMD) Chairman Charles M. Diker sold 20,500 shares worth $US2,032,538 on October 04. The selling price was $US99.15.

12 July 2017

Cantel Medical chairman Charles M. Diker sells

Cantel Medical (NYSE:CMD) Chairman Charles M. Diker sold 8,000 shares worth $US604,256 on July 10. The selling price was $US75.53. The shares hit a one-month low on the day.

12 July 2017

Cantel Medical chairman Charles M. Diker sells

Cantel Medical (NYSE:CMD) Chairman Charles M. Diker sold 13,000 shares worth $US982,198 on July 11. The selling price was $US75.55. The shares hit a five-day high on the day.

12 July 2017

Cantel Medical chairman Charles M. Diker sells

Cantel Medical (NYSE:CMD) Chairman Charles M. Diker sold 14,000 shares worth $US1,056,702 on July 12. The selling price was $US75.48. The shares hit a six-day high on the day.

13 June 2017

Cantel Medical chairman Charles M. Diker sells

Cantel Medical (NYSE:CMD) Chairman Charles M. Diker sold 11,298 shares worth $US863,271 on June 09. The selling price was $US76.41.

Source: www.BuySellSignals.com